Lexi Ventures

Lexi Ventures is a Menlo Park-based venture capital firm founded in 2023 by Jonah Probell, focused exclusively on seed-stage genetic engineering startups. Branded as Genetic Engineering Capital, the firm invests in US-based companies building around DNA, RNA, cells, and omics technologies. Probell brings 25 years of startup experience across seven companies in founder, executive, and engineering roles, having achieved two IPOs, 16 granted patents, and authored two books. The firm's thesis is that the genetic engineering revolution will be among the most value-creating venture categories of the next decade, as biology has transitioned from science to engineering. Lexi invests $50,000 to $500,000 with a sweet spot of $250,000, deploying approximately 10 investments annually and ranking among the top 20 VC funds active in the gene tech niche. The portfolio of 11-plus companies includes Kopra Bio (T-cell immunotherapy for solid tumors, most recent investment October 2025), ParcelBio (programmable mRNA delivery), KiraGen Bio (high-fidelity CRISPR tools, raised $2.5 million, Harvard Innovation Lab), QUiCKR Bio (gene editing quality control), Melio (rapid newborn pathogen diagnostics), AlkaLi Labs (biomining with microbes for critical minerals), Glyphic Bio (single-molecule protein sequencing), Syntensor (AI simulation for clinical trials), TippingPoint (precision genetic medicines for rare pediatric diseases), Taxa (bio-engineered probiotic skincare), and Crank Bio (RNA-based antisense therapeutics for rare diseases). Co-investors include IndieBio/SOSV and Activate Global. Lexi Ventures participates in the BIO Investor Forum and operates as a specialist conviction fund, aiming to be the first check for founders building at the frontier of genetic engineering. The firm's narrow focus gives it genuine domain depth — Probell evaluates deals not as a financial generalist but as someone who has built and scaled scientific companies from the lab bench outward.